Johnson & Johnson's anti-cancer drug Imbruvica may become one of the best blood cancer drugs

Source: Bio exploration 2014-08-05 as early as December 2011, Johnson & Johnson signed a license agreement with pharmacyclics to jointly develop and commercialize imbruvica, and plans to use imbruvica in the treatment of chronic lymphocytic leukemia In February this year, the U.S Food and Drug Administration (FDA) announced the new indication application of imbruvica for patients with chronic lymphoblastic leukemia (CLL) who have received treatment but have no effect; in July, imbruvica was approved by the FDA's new drug supplement application (SNDA), and the newly approved adaptation was chronic lymphoblastic leukemia (CLL) with del 17p gene mutation Last week, pharmacyclics said it had a quarterly loss of 26 cents a share, well above the 11 cents Wall Street analysts had predicted Although the company is in a loss state, the focus of long-term investors is not limited to this aspect At present, imbruvica has been approved to treat multiple forms of lymphoma, creating a value of $113 million, far higher than the $83 million predicted by forecasters Imbruvica's sales even exceed those of some well-known anticancer drugs, such as Revlimid from celgene and Gleevec from Novartis This news is very good for pharmacyclics and Johnson & Johnson It indicates that imbruvica is on the way to a promising future, or will become one of the best blood cancer drugs The quarterly sales of cancer drugs in the United States about imbruvica imbruvica is the first once-a-day, single preparation, oral Burton tyrosine kinase (Btk) inhibitor, which can inhibit the replication and metastasis of tumor cells by blocking Btk, so as to play an anti-cancer role Chronic lymphocytic leukemia (CLL) CLL is a rare disease of blood and bone marrow, which gradually worsens over time and causes the increase of B lymphocytes The National Cancer Institute estimates that 15680 people were diagnosed with CLL and 4580 died in 2013